| 产品名称： | KG-1 |
|---|---|
| 商品货号： | TS211702 |
| Organism： | Homo sapiens, human |
| Product Format： | frozen |
| Morphology： | lymphoblast-like |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute myelogenous leukemia |
| Age： | 59 years |
| Gender： | male |
| Ethnicity： | Caucasian |
| Applications： | Responsive to colony stimulating activity (CSA). Produces high levels of human leukocyte interferon upon induction by paramyxoviridae species. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Clinical Data： | male Caucasian 59 years |
| Genes Expressed： | human leukocyte interferon |
| Cellular Products： | human leukocyte interferon |
| Comments： | Responsive to colony stimulating activity (CSA). Produces high levels of human leukocyte interferon upon induction by paramyxoviridae species. See also ATCC CCL-246. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 X 10(5) viable cells/ml. Interval: Maintain between 2 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 7 D13S317: 11,12 D16S539: 10,11 D5S818: 13 D7S820: 8,10 THO1: 7,8 TPOX: 7,9 vWA: 14,19 |
| Name of Depositor： | Genentech, Inc. |
| U.S. Patent Number： | |
| References： | Koeffler HP, Golde DW. Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. Science 200: 1153-1154, 1978. PubMed: 306682 Goeddel DV. Hybrid human leukocyte interferons. US Patent 4,678,751 dated Jul 7 1987 |
| Cross References： | Nucleotide (GenBank) : E00473 Human leukocyte interferon A (LeIFA) gene and its flanking sequence. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | KG-1 |
|---|---|
| 商品货号： | TS211702 |
| Organism： | Homo sapiens, human |
| Product Format： | frozen |
| Morphology： | lymphoblast-like |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute myelogenous leukemia |
| Age： | 59 years |
| Gender： | male |
| Ethnicity： | Caucasian |
| Applications： | Responsive to colony stimulating activity (CSA). Produces high levels of human leukocyte interferon upon induction by paramyxoviridae species. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Clinical Data： | male Caucasian 59 years |
| Genes Expressed： | human leukocyte interferon |
| Cellular Products： | human leukocyte interferon |
| Comments： | Responsive to colony stimulating activity (CSA). Produces high levels of human leukocyte interferon upon induction by paramyxoviridae species. See also ATCC CCL-246. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 X 10(5) viable cells/ml. Interval: Maintain between 2 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| STR Profile： | Amelogenin: X,Y CSF1PO: 7 D13S317: 11,12 D16S539: 10,11 D5S818: 13 D7S820: 8,10 THO1: 7,8 TPOX: 7,9 vWA: 14,19 |
| Name of Depositor： | Genentech, Inc. |
| U.S. Patent Number： | |
| References： | Koeffler HP, Golde DW. Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. Science 200: 1153-1154, 1978. PubMed: 306682 Goeddel DV. Hybrid human leukocyte interferons. US Patent 4,678,751 dated Jul 7 1987 |
| Cross References： | Nucleotide (GenBank) : E00473 Human leukocyte interferon A (LeIFA) gene and its flanking sequence. |
